PURE Bioscience 8-K Item 2.02: FY2025 results press release furnished

Rhea-AI Filing Summary

PURE Bioscience (PURE) furnished an 8‑K under Item 2.02 announcing a press release with financial results for the fiscal year ended July 31, 2025. The press release is attached as Exhibit 99.1. The company states the information is being furnished, not filed, and will not be incorporated by reference into other SEC filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001006028 0001006028 2025-10-29 2025-10-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

PURE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-14468		33-0530289
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

771 Jamacha Rd., #512 El Cajon, California		92019
(Address of principal executive offices)		(Zip Code)

9669 Hermosa Avenue Rancho Cucamonga, California		91730
(Address of principal executive offices)		(Zip Code)

(Former name or former address, if changed since last report)

Registrant’s telephone number, including area code: (619) 596-8600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On October 29, 2025, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal year ended July 31, 2025 and related information. A copy of the press release is attached as Exhibit 99.1.

The information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

	99.1	Press Release, dated October 29, 2025.
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PURE BIOSCIENCE, INC.
Dated: October 29, 2025	By:	/s/ Robert F. Bartlett
		Robert F. Bartlett
		Chief Executive Officer

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release, dated October 29, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

FAQ

What did PURE (PURE) announce in this 8-K?

The company furnished a press release announcing financial results for the fiscal year ended July 31, 2025, attached as Exhibit 99.1.

Which 8-K item applies to PURE Bioscience’s filing?

Item 2.02, Results of Operations and Financial Condition.

Is the information in this 8-K considered filed with the SEC?

No. The company states the information is furnished and not filed, and it is not subject to Section 18 liabilities.

Will the press release be incorporated by reference into other SEC documents?

No. The company specifies it will not be incorporated by reference into any registration statement or other document.

What exhibit contains PURE Bioscience’s press release?

Exhibit 99.1 contains the press release dated October 29, 2025.

What fiscal period does the press release cover for PURE (PURE)?

The fiscal year ended July 31, 2025.